Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Inactive · Last trade price
on Jan 23, 2024
Orchard Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2016 |
| Revenue | 21.84 | 22.66 | 1.68 | 2.6 | 2.51 | 2.08 | Upgrade
|
| Revenue Growth (YoY) | 35.21% | 1252.54% | -35.45% | 3.26% | 21.05% | - | Upgrade
|
| Cost of Revenue | 79.52 | 99.17 | 86.68 | 85.34 | 0.81 | 0.42 | Upgrade
|
| Gross Profit | -57.68 | -76.52 | -85 | -82.74 | 1.71 | 1.65 | Upgrade
|
| Selling, General & Admin | 44.34 | 48.79 | 54.42 | 60.99 | 57.22 | 31.37 | Upgrade
|
| Research & Development | - | - | - | - | 117.36 | 205.32 | Upgrade
|
| Operating Expenses | 44.34 | 48.79 | 54.42 | 60.99 | 174.58 | 236.69 | Upgrade
|
| Operating Income | -102.01 | -125.31 | -139.43 | -143.73 | -172.87 | -235.03 | Upgrade
|
| Interest Expense | -3.8 | -3.08 | -2.5 | -2.33 | -1.54 | - | Upgrade
|
| Interest & Investment Income | 4.78 | 1.54 | 0.41 | 3.19 | 7.36 | 1.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 25.8 | -24.3 | -1.2 | 3.4 | 1.4 | 4.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.87 | -0.42 | 1.48 | 0.78 | -0.69 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -73.36 | -151.56 | -141.23 | -138.69 | -166.34 | -229.53 | Upgrade
|
| Merger & Restructuring Charges | -0 | -1.78 | -1.01 | -9.25 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.31 | 0.31 | -1.51 | -0.77 | 0.68 | - | Upgrade
|
| Other Unusual Items | - | - | - | -4 | - | - | Upgrade
|
| Pretax Income | -73.06 | -153.03 | -143.76 | -152.71 | -165.66 | -229.53 | Upgrade
|
| Income Tax Expense | -0.14 | -2.37 | 0.83 | -0.73 | -2.24 | 0.97 | Upgrade
|
| Net Income | -72.92 | -150.66 | -144.58 | -151.98 | -163.42 | -230.5 | Upgrade
|
| Net Income to Common | -72.92 | -150.66 | -144.58 | -151.98 | -163.42 | -230.5 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 13 | 12 | 10 | 9 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 13 | 12 | 10 | 9 | 2 | Upgrade
|
| Shares Change (YoY) | 34.70% | 3.24% | 24.65% | 6.65% | 313.31% | 154.25% | Upgrade
|
| EPS (Basic) | -4.24 | -11.77 | -11.66 | -15.28 | -17.53 | -102.17 | Upgrade
|
| EPS (Diluted) | -4.24 | -11.77 | -11.66 | -15.28 | -17.53 | -102.17 | Upgrade
|
| Free Cash Flow | -94.41 | -82.5 | -127.45 | -138.94 | -170.5 | -101.57 | Upgrade
|
| Free Cash Flow Per Share | -5.48 | -6.45 | -10.28 | -13.97 | -18.29 | -45.02 | Upgrade
|
| Gross Margin | -264.11% | - | - | - | 67.97% | 79.67% | Upgrade
|
| Operating Margin | -467.12% | -553.11% | -8323.88% | -5538.65% | -6879.15% | -11321.34% | Upgrade
|
| Profit Margin | -333.90% | -665.02% | -8631.88% | -5856.61% | -6503.06% | -11102.84% | Upgrade
|
| Free Cash Flow Margin | -432.30% | -364.16% | -7608.66% | -5354.22% | -6784.64% | -4892.49% | Upgrade
|
| EBITDA | -99.34 | -122.57 | -137.1 | -141.72 | -171.2 | -233.83 | Upgrade
|
| D&A For EBITDA | 2.67 | 2.74 | 2.33 | 2 | 1.68 | 1.2 | Upgrade
|
| EBIT | -102.01 | -125.31 | -139.43 | -143.73 | -172.87 | -235.03 | Upgrade
|
| Revenue as Reported | 21.84 | 22.66 | 1.68 | 2.6 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.